

References on Epalrestat

- Baba M, Kimura K, Suda T, Yagihashi S; Aomori Diabetic Study (ADNS) Group. 2006. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients. *J Peripher Nerv Syst.* Jun;11(2):176-8.
- Carrington A, Shaw J, Van Schie C, Abbott C, Vileikyte L, Boulton A. 2002. Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period. *Diabetes Care.* 25:2010-2015.
- Dogen H, Hayashi Y, Matsue Y. 1988. Effect of aldose reductase inhibitor (ONO-2235) in diabetic neuropathy. Polyol Pathway and Its Role in Diabetic Complications. 1988 Sakamoto N *et al.* (eds).
- Goldfine A. 2008. Assessing the cardiovascular safety of diabetes therapies. *N Eng J Med.* 359;11.
- Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kikkawa R. 1995. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. *Biomed Pharmacother.* 49(6):269-77.
- Goto Y, Kito S, Matsuoka K, Sakamoto N, Shigeta Y. 1988. Clinical effect of aldose reductase inhibitor (Epalrestat, ONO-2235) on diabetic neuropathy. Multi-institutional studies. Polyol Pathway and Its Role in Diabetic Complications. Sakamoto N *et al.* (eds).
- Hotta N, Kawamori R, Fukuda M, Shigata Y. 2012. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression on diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy. *Diabetic Medicine.* 29, 1529-1533.
- Hotta N, Kawamori R, Atsumi Y, Baba M, Kishikawa H, Nakamura J, Oikawa S, Yamada N, Yasuda H, Shigata Y. 2008. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor epalrestat. *Diabetic Medicine* 25, 818-825.
- Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, Shigeta Y. 2006. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. *Diabetes Care.* Jul; 29(7):1538-44.
- Hotta N, Kakuta H, Fukasawa H, Ando F, Miyake Y, Awaya S, Sakamoto N. Diabetic retinopathy. Polyol Pathway and Its Role in Diabetic Complications. 1988 Sakamoto N *et al.* (eds).

Hotta N, Kakuta H, Ando F, Miyake Y, Awaya S, Fukasawa H, Koh N, Sakakibara F, Sakamoto N. Diabetic retinopathy. Current Concepts of Aldose Reductase and its Inhibitions . 1990 Sakamoto N *et al.* (eds).

Hotta N, Kakuta H, Ando F, Sakamoto N. Clinical trial of aldose reductase inhibitor ONO-2235: effect on diabetic retinopathy. Polyol Pathway and Its Role in Diabetic Complications. 1988 Sakamoto N *et al.* (eds).

Hotta N, Sakamoto N, Shigeta Y, Kikkawa R, Goto Y. 1996. Clinical Investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. *Journal of Diabetes and Its Complications*. 10:168-172.

Ikeda T *et al.* 1999. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus. *Diabetes Research and Clinical Practice*. 43; 193-198.

Ikezawa M, Takeiuchi M, Yatabe K, Kono Y, Tan K, Yamamoto K, Iwata M. Clinical and neurophysiological effects of epalrestat on diabetic neuropathy. Diabetic neuropathy: new concepts and insights. 1995. Hotta *et al* (eds).

Kaji R, Kohara N, Oka N, Katayama M, Kojima Y, Hirota N, Seino Y, Kimura J. Clinical trial of aldose reductase inhibitor epalrestat: electrophysiological evaluation. Diabetic neuropathy: new concepts and insights. 1995. Hotta *et al* (eds).

Maladkar M, Rajadhyaksha G, Venkatswamy N, Hariharan R, Lohati S. 2009. Efficacy, safety and tolerability of epalrestat compared to methylcobalamin in patients with diabetic neuropathy. *International Journal of Diabetes in Developing Countries*, 29, 28-34.

Maladkar M, Saggi N, Moralwar P, Mhate A, Zemse D, Bhoraskar A. 2013. Evaluation of efficacy and safety of epalrestat in combination with cobalamin in patients with diabetic neuropathy in a randomized comparative trial. *J Diab Mellitus*. 3; 1:22-26.

Misawa S, Kuwabara S, Kanai K, Tamura N, Nakata M, Sawai S, Yagui K, Hattori T. 2006. Aldose reductase inhibition alters nodal Na⁺ currents and nerve conduction in human diabetics. *Neurology*. 66:1645-1649.

Nakayama M, Nakamura J, Hamada Y, Chaya S, Mizubayashi R, Yasuda Y, Kamiya H, Koh N, Hotta N. 2001. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy. *Diabetes Care*. Jun;24(6):1093-8

Nakayama M, Nakamura J, Hamada Y, Chaya S, Mizubayashi R, Yasuda Y, Kamiya H, Koh N, Hotta N. 2001. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy. *Diabetes Care*. Jun; 24(6):1093-8

Ramirez M, Borja N. 2008. Epalrestat: An aldose reductase inhibitor for the treatment of diabetic neuropathy. *Pharmacotherapy*. 28:(5): 646-655.

Ramirez MA, Borja NL 2008. (REVIEW) Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. *Pharmacotherapy*. May;28(5):646-55

Sharma S, Sharma N. 2008. Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: an Indian perspective. *Ann Indian Acad Neurology*. 11; 231-235.

Suzuki E, Shibata T, Yasuda K, Takeda N, Inouye H, Ishizuka T, Yasuda K. Can administration of an aldose reductase inhibitor improve diabetic neuropathy? Diabetic neuropathy: new concepts and insights. 1995. Hotta *et al* (eds).